4,N,N-trimethyltryptamine | 28289-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,N,N-trimethyltryptamine
• 英文别名: N,N-dimethyl-2-(4-methyl-1H-indol-3-yl)ethanamine
• CAS: 28289-23-8
• 化学式: C₁₃H₁₈N₂
• 分子量: 202.299
• InChiKey: SJLWCURJFQWOAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-甲基吲哚 在 lithium aluminium tetrahydride 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 生成 4,N,N-trimethyltryptamine
  参考文献：
  名称：

  Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines

  摘要：

  A novel series of N,N-dimethylisotryptamine (isoDMT) derivatives, i.e., derivatives of 1-[2-(dimethylamino)ethyl]indole, was prepared and found to be isosteric with their corresponding N,N-dimethyltryptamine (DMT) counterparts with respect to serotonin receptor (rat fundus) affinity. Whereas the isoDMT derivatives possessed a greater affinity than did their corresponding DMT derivatives, they were relatively ineffective in displacing [3H]-5-HT binding from rat brain (cortex) homogenates. In a drug discrimination paradigm, using rats as subjects, 6-OMe-isoDMT produced effects similar to those of 5-OMe-DMT. Attempts to antagonize the discriminative stimulus effects of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) using two of the isoDMT derivatives proved unsuccessful.

  DOI：

  10.1021/jm00367a008

文献信息

• PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS
  申请人：Ground Fluor Pharmaceuticals, Inc.

  公开号：US20140121371A1

  公开（公告）日：2014-05-01

  This disclosure relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated, iodinated, astatinated and radiofluorinated aromatic compounds.

  这项披露涉及用于制备二芳基碘盐的工艺和试剂，该类试剂可用于制备氟化、碘化、砹化和放射性氟化芳香化合物。
• TRYPTAMINE ANALOGUES, THEIR SYNTHESIS AND THEIR USE AS 5-HT1-LIKE RECEPTORS OR 5-HT2 RECEPTOR AGONISTES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0593513B1

  公开（公告）日：1998-10-28
• US9278959B2
  申请人：——

  公开号：US9278959B2

  公开（公告）日：2016-03-08
• [EN] GENETIC ENGINEERING OF FUNGI TO MODULATE TRYPTAMINE EXPRESSION<br/>[FR] GÉNIE GÉNÉTIQUE DE CHAMPIGNONS POUR MODULER L'EXPRESSION DE TRYPTAMINE
  申请人：INTIMA BIOSCIENCE INC

  公开号：WO2021067626A2

  公开（公告）日：2021-04-08

  Provided herein are methods for modulating the psilocybin biosynthesis pathway in fungi or other organisms. Also provided are genetically modified fungi and organisms with induced and/or increased expression of psilocybin and psilocin and psilocybin and/or psi!ocin compositions generated by the provided methods.
• [EN] COMPOSITIONS AND METHODS FOR TREATING MIGRAINE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA MIGRAINE
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115798A2

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating or preventing migraine, or symptoms thereof, with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., migraine), or symptoms thereof (e.g., anxiety or depression).